NEW YORK (GenomeWeb) – Molecular diagnostics firm Evogen and biopharmaceutical company UCB said today that they are collaborating on the development of a proteomics-based diagnostic for the identification of epileptic seizures.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.